- Home
- BENF vs QLGN Comparison
BENF vs QLGN Comparison
Compare BENF & QLGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BENF
- QLGN
- Stock Information
- Founded
- BENF 2003
- QLGN 1996
- Country
- BENF United States
- QLGN United States
- Employees
- BENF N/A
- QLGN N/A
- Industry
- BENF Blank Checks
- QLGN Biotechnology: Pharmaceutical Preparations
- Sector
- BENF Finance
- QLGN Health Care
- Exchange
- BENF Nasdaq
- QLGN Nasdaq
- Market Cap
- BENF 2.7M
- QLGN 3.1M
- IPO Year
- BENF N/A
- QLGN N/A
- Fundamental
- Price
- BENF $0.31
- QLGN $1.90
- Analyst Decision
- BENF
- QLGN
- Analyst Count
- BENF 0
- QLGN 0
- Target Price
- BENF N/A
- QLGN N/A
- AVG Volume (30 Days)
- BENF 335.3K
- QLGN 116.2K
- Earning Date
- BENF 08-26-2025
- QLGN 08-26-2025
- Dividend Yield
- BENF N/A
- QLGN N/A
- EPS Growth
- BENF N/A
- QLGN N/A
- EPS
- BENF N/A
- QLGN N/A
- Revenue
- BENF N/A
- QLGN N/A
- Revenue This Year
- BENF N/A
- QLGN N/A
- Revenue Next Year
- BENF N/A
- QLGN N/A
- P/E Ratio
- BENF N/A
- QLGN N/A
- Revenue Growth
- BENF N/A
- QLGN N/A
- 52 Week Low
- BENF $0.22
- QLGN $1.61
- 52 Week High
- BENF $3.33
- QLGN $11.50
- Technical
- Relative Strength Index (RSI)
- BENF 46.73
- QLGN 32.76
- Support Level
- BENF $0.27
- QLGN $1.61
- Resistance Level
- BENF $0.34
- QLGN $1.91
- Average True Range (ATR)
- BENF 0.03
- QLGN 0.16
- MACD
- BENF -0.00
- QLGN 0.02
- Stochastic Oscillator
- BENF 32.37
- QLGN 29.74
About BENF Beneficient
Beneficient is a technology-enabled financial services holding company that (together with its subsidiaries) provides simple, rapid, and cost-effective liquidity solutions to participants in the alternative asset industry through its end-to-end online platform, AltAccess. BCG's products and services are designed to meet the unmet needs of mid-to-high net-worth individual investors, small-to-midsize institutional investors, family offices, and fund general partners. Its bespoke liquidity solutions for otherwise illiquid alternative asset investments are delivered through proprietary technology and an innovative financing and trust structure. It has three reportable segments consisting of Ben Liquidity, Ben Custody and Customer ExAlt Trusts.
About QLGN Qualigen Therapeutics Inc.
Qualigen Therapeutics Inc is an early-clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer. The company's business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program. The company's program, QN-302, is an investigational small-molecule G-quadruplexes (G4)-selective transcription inhibitor with binding affinity to G4s prevalent in cancer cells.